These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 21383647

  • 1. Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients.
    Bakken GV, Rudberg I, Molden E, Refsum H, Hermann M.
    Ther Drug Monit; 2011 Apr; 33(2):222-6. PubMed ID: 21383647
    [Abstract] [Full Text] [Related]

  • 2. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
    Bakken GV, Molden E, Knutsen K, Lunder N, Hermann M.
    Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
    [Abstract] [Full Text] [Related]

  • 3. Impact of genetic variability in CYP2D6, CYP3A5, and ABCB1 on serum concentrations of quetiapine and N-desalkylquetiapine in psychiatric patients.
    Bakken GV, Molden E, Hermann M.
    Ther Drug Monit; 2015 Apr; 37(2):256-61. PubMed ID: 25254417
    [Abstract] [Full Text] [Related]

  • 4. Plasma concentrations of quetiapine, N-desalkylquetiapine, o-desalkylquetiapine, 7-hydroxyquetiapine, and quetiapine sulfoxide in relation to quetiapine dose, formulation, and other factors.
    Fisher DS, Handley SA, Flanagan RJ, Taylor DM.
    Ther Drug Monit; 2012 Aug; 34(4):415-21. PubMed ID: 22777152
    [Abstract] [Full Text] [Related]

  • 5. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service.
    Castberg I, Skogvoll E, Spigset O.
    J Clin Psychiatry; 2007 Oct; 68(10):1540-5. PubMed ID: 17960969
    [Abstract] [Full Text] [Related]

  • 6. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5.
    Bakken GV, Rudberg I, Christensen H, Molden E, Refsum H, Hermann M.
    Drug Metab Dispos; 2009 Feb; 37(2):254-8. PubMed ID: 19022943
    [Abstract] [Full Text] [Related]

  • 7. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.
    Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB.
    Br J Clin Pharmacol; 2006 Jan; 61(1):58-69. PubMed ID: 16390352
    [Abstract] [Full Text] [Related]

  • 8. Quetiapine serum concentrations in psychiatric patients: the influence of comedication.
    Hasselstrøm J, Linnet K.
    Ther Drug Monit; 2004 Oct; 26(5):486-91. PubMed ID: 15385830
    [Abstract] [Full Text] [Related]

  • 9. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity.
    Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL.
    Neuropsychopharmacology; 2008 Sep; 33(10):2303-12. PubMed ID: 18059438
    [Abstract] [Full Text] [Related]

  • 10. Effect of N-Desalkylquetiapine/Quetiapine Plasma Level Ratio on Anxiety and Depression in Bipolar Disorder: A Prospective Observational Study.
    Rovera C, Mauri MC, Di Pace C, Paletta S, Reggiori A, Ciappolino V, Cattaneo D, Baldelli S, Clementi E, Altamura AC.
    Ther Drug Monit; 2017 Aug; 39(4):441-445. PubMed ID: 28486308
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of quetiapine and norquetiapine on anxiety and depression in major psychoses using a pharmacokinetic approach: a prospective observational study.
    Altamura AC, Moliterno D, Paletta S, Buoli M, Dell'osso B, Mauri MC, Bareggi SR.
    Clin Drug Investig; 2012 Mar 01; 32(3):213-9. PubMed ID: 22299714
    [Abstract] [Full Text] [Related]

  • 15. Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents.
    Johnson TN, Zhou D, Bui KH.
    Biopharm Drug Dispos; 2014 Sep 01; 35(6):341-52. PubMed ID: 24797229
    [Abstract] [Full Text] [Related]

  • 16. In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions.
    Hasselstrøm J, Linnet K.
    Drug Metabol Drug Interact; 2006 Sep 01; 21(3-4):187-211. PubMed ID: 16841513
    [Abstract] [Full Text] [Related]

  • 17. Use of high doses of quetiapine in bipolar disorder episodes are not linked to high activity of cytochrome P4503A4 and/or cytochrome P4502D6.
    Khazaal Y, Preisig M, Chatton A, Kaufmann N, Bilancioni R, Eap CB.
    Psychiatr Q; 2013 Sep 01; 84(3):329-35. PubMed ID: 23230007
    [Abstract] [Full Text] [Related]

  • 18. Comparison of D₂ dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects.
    Nord M, Nyberg S, Brogren J, Jucaite A, Halldin C, Farde L.
    Int J Neuropsychopharmacol; 2011 Nov 01; 14(10):1357-66. PubMed ID: 21477416
    [Abstract] [Full Text] [Related]

  • 19. 4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients.
    Gjestad C, Haslemo T, Andreassen OA, Molden E.
    Br J Clin Pharmacol; 2017 Nov 01; 83(11):2398-2405. PubMed ID: 28585378
    [Abstract] [Full Text] [Related]

  • 20. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.
    Potkin SG, Preskorn S, Hochfeld M, Meng X.
    J Clin Psychopharmacol; 2013 Feb 01; 33(1):3-10. PubMed ID: 23277250
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.